Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (17)

2024

  1. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

  2. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

    Journal of Clinical Oncology

  3. New promises and challenges in the treatment of advanced non-small-cell lung cancer

    The Lancet, Vol. 404, Núm. 10454, pp. 803-822

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  2. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375

  3. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

    ESMO Open, Vol. 8, Núm. 4

2022

  1. Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

    npj Breast Cancer, Vol. 8, Núm. 1

  2. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

2017

  1. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

    Journal of Clinical Oncology

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): Pooled subset analyses from two randomized trials

    Annals of Oncology, Vol. 27, Núm. 3, pp. 423-429

2014

  1. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 12, pp. 1369-1378

2013

  1. Epidermal growth factor receptor inhibition in lung cancer: Status 2012

    Journal of Thoracic Oncology, Vol. 8, Núm. 3, pp. 373-384

  2. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

    Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417

2012

  1. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

    Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179

2010

  1. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 6, pp. 2664-2671

2008

  1. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 26, Núm. 33, pp. 5407-5415